Close

Quest PharmaTech to start Phase II Oregovomab clinical trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

Quest PharmaTech has got clearance from FDA to initiate US sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

The aim of the trial will be to know whether closed oregovomab in relation with front-line chemotherapy will generate the same or an improved immunity and clinical response.

Out of the three participating U.S. Centres in the trial two have got needed approvals as the third centre awaits institutional review board (IRB) approval.

Quest pharma Chairman Christopher Nicodemus said,”A systemic study of combinatorial immunisation strategies such as the current trial with evidence based preliminary observations has the potential of revolutionising cancer therapy and may lead to important commercial applications.”

Quest CEO Madi R. Madiyalakan said,”We are pleased with the interest from the U.S. centres to participate in this important clinical trial. The additional centres will not only speed up patient enrolment for the study, but will raise the profile and awareness of Quest’s lead immunotherapy product in the ovarian cancer community in North America.”

Latest stories

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back